Alfred Demaria
Neurology · Wilmington, NCNPI 1619085545
Payments from drug & device makers
Across 258 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$475
- Supernus Pharmaceuticals, Inc.$338
- Sunovion Pharmaceuticals Inc.$304
- Amgen$298
- Livanova USA, Inc.$297
- Teva Pharmaceuticals USA, Inc.$294
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$571%
- Food & beverage$3,72393%
- Education$2376%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 25 | $475 |
| Supernus Pharmaceuticals, Inc. | 30 | $338 |
| Sunovion Pharmaceuticals Inc. | 24 | $304 |
| Amgen | 14 | $298 |
| Livanova USA, Inc. | 8 | $297 |
| Teva Pharmaceuticals USA, Inc. | 29 | $294 |
| AbbVie | 25 | $282 |
| Eisai Inc. | 13 | $280 |
| Novartis | 9 | $133 |
| Avanir Pharmaceuticals, Inc. | 6 | $128 |
| EMD Serono, Inc. | 8 | $116 |
| AstraZeneca | 5 | $93 |
| Lundbeck LLC | 4 | $91 |
| Aquestive Therapeutics, Inc. | 5 | $87 |
| Grifols USA, LLC | 5 | $84 |
| Tanabe Pharma America, Inc. | 3 | $68 |
| Sanofi | 5 | $58 |
| Acorda Therapeutics, Inc | 4 | $57 |
| Assertio Therapeutics, Inc. | 4 | $55 |
| Greenwich Biosciences, Inc. | 3 | $43 |
| Aprecia Pharmaceuticals, LLC | 2 | $42 |
| Genentech USA, Inc. | 2 | $37 |
| MDD US Operations, LLC | 2 | $35 |
| SK Life Science, Inc. | 2 | $34 |
| Adamas Pharmaceuticals, Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Amneal Pharmaceuticals LLC | 2 | $25 |
| Zyla Life Sciences, Inc. | 2 | $24 |
| Promius Pharma LLC | 1 | $23 |
| Biogen | 1 | $18 |
| Merz North America, Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| Harmony Biosciences LLC | 1 | $13 |
| Abbott | 1 | $12 |
| Upsher-smith Laboratories LLC | 1 | $11 |
| Pfizer | 1 | $11 |
How this compares
$4,017 in reported general payments places this provider in the 60th percentile of 566 neurology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 24 | $504 |
Paid to pharmacies, not to this prescriber.
Other neurology in Wilmington
- Mohammad BolouriCharlotte$16.6M
- Katherine PetersDurham$11M
- John ScagnelliRaleigh$9.3M
- T RaoCharlotte$4M
- Pramod SethiGreensboro$2.9M
- Robert ArmstrongAsheville$2.7M
- Casey JeffreysRaleigh$2.2M
- Mitchell IsaacWinston Salem$2.2M
- Vern JuelDurham$2M
- Marshall FreemanGreensboro$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.